| VXL Stock | | | CAD 0.01 0.00 0.00% |
Chairman
David Goren is CEO Chairman of Vaxil Bio
| Address | 3400 One First Canadian Place, Toronto, ON, Canada, M5X 1A4 |
| Phone | 416-227-9667 |
| Web | https://www.vaxil-bio.com |
Vaxil Bio Management Efficiency
The company has return on total asset
(ROA) of
(0.1018) % which means that it has lost $0.1018 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.2026) %, meaning that it generated substantial loss on money invested by shareholders. Vaxil Bio's management efficiency ratios could be used to measure how well Vaxil Bio manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Tangible Assets is likely to drop to -0.0003 in 2024.
Return On Capital Employed is likely to drop to -0.3 in 2024. At this time, Vaxil Bio's
Net Tangible Assets are fairly stable compared to the past year.
Non Currrent Assets Other is likely to climb to about 88
K in 2024, whereas
Total Assets are likely to drop slightly above 853.8
K in 2024.
Vaxil Bio has accumulated 85
K in total debt with debt to equity ratio
(D/E) of 11.2, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vaxil Bio has a current ratio of 1.05, suggesting that it
may not have the ability to pay its financial obligations in time and when they become due. Debt can assist Vaxil Bio until it has trouble settling it off, either with new capital or with free cash flow. So, Vaxil Bio's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Vaxil Bio sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Vaxil to invest in growth at high rates of return. When we think about Vaxil Bio's use of debt, we should always consider it together with cash and equity.
Vaxil Bio Ltd., an immunotherapy biotech company, engages in the research and development of immunotherapies for cancer and infectious diseases in Israel. The company was founded in 2006 and is headquartered in Toronto, Canada. VAXIL BIO is traded on TSX Venture Exchange in Canada. Vaxil Bio (VXL) is traded on TSX Venture Exchange in Canada and employs 3 people. Vaxil Bio is listed under Biotechnology category by Fama And French industry classification.
Management Performance
Vaxil Bio Management Team
Elected by the shareholders, the Vaxil Bio's board of directors comprises two types of representatives: Vaxil Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vaxil. The board's role is to monitor Vaxil Bio's management team and ensure that shareholders' interests are well served. Vaxil Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vaxil Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
Vaxil Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vaxil Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Vaxil Stock Analysis
When running Vaxil Bio's price analysis, check to
measure Vaxil Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxil Bio is operating at the current time. Most of Vaxil Bio's value examination focuses on studying past and present price action to
predict the probability of Vaxil Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxil Bio's price. Additionally, you may evaluate how the addition of Vaxil Bio to your portfolios can decrease your overall portfolio volatility.